Beruflich Dokumente
Kultur Dokumente
.
Corporate Programs Department ISO
1979 Marcus Avenue
Lake Success, NY 11042-1002 9001:2008
I www.ipro.org CERTIFIED
October 8, 2015
Dear :
IPRO has completed review of all documentation submitted relative to your request for external appeal
on behalf of and has determined that the decision of Oxford Health Plans- NY to
deny coverage for Harvoni should be reversed.
Review of this appeal was conducted by a physician reviewer, who is Board Certified in Internal
Medicine and Gastroenterology. This reviewer is licensed in New York, and is on staff at two medical
centers. This reviewer also has a faculty appointment at a college of medicine. Professional
organization affiliations include the American Society of Gastroenterologic Endoscopy and American
College of Gastroenterology. IPRO has screened this clinical reviewer for any prohibited material
affiliation and has determined that none exists. IPRO has no organizational conflict of interest in the
review of this appeal.
The case was received by IPRO on 9/10/15. The review was conducted on 10/7/ 15. A decision was
rendered 10/8/15.
Letter from Nina Doss. New York State Department of Financial Serv ices to T . Giorgio, IPRO dated
9/ 10/15
Letter from Nina Doss, New York State Department of Financial Services to dated
9/10/15
Letter from Nina Doss, New York State Department of Financial Services to Abby Seay, Appeals
and Grievances, Oxford Health Plans of New York dated 9/10/15
New York State External Appeal Application filed by for
undated
Patient Consent for the Release of Records for NYS External Appeal Application signed by
dated 8/28/15
Letter from Robert F, Resolving Analyst, United Healthcare Oxford to dated
8/ 14/15
Letter from Optum Rx, United Healthcare Oxford to dated 7/28/15
Letter from to Whom It May
Concern dated 8/4/15
Letter from Andrea Terdik, Regulatory Affairs Analyst/External Agent, United Healthcare Oxford to
T. Giorgio, IPRO dated 9/15/15
Letter from to dated 12/17/14
To: FaxServer Fro.: IPRO Fax : 516-328-2310 OCT- 08-2015-13: 15 Page:004 of 005
October 8, 2015
.
Page 2
Issue:
Lab tests included for review revealed a Hepatitis C RNA Detection by PCR level of 939910.
The insurer has denied coverage for Harvoni. They stated in a final adverse determination letter
dated 8/14/15 that the plan would approve coverage for this medicine in the patient had stage 3
or 4 liver fibrosis. The insurer added that this must be documented by testing. They explained
that the patient might also be covered if there were serious complications of Hepatitis C virus
outside of the patient's liver, or have Human Immunodeficiency Virus infection. The insurer
maintained that since the patient did not have this, Harvoni was not considered to be medically
necessary in the patient's case.
is appealing.
October 8, 2015
.
Page 3
Reviewer Findings:
The patient has chronic Hepatitis C genotype 1a. had previous treatment with boceprevir but
needed to stop it due to neutropenia. has elevated liver enzymes and has a fibrosis stage of
F1-F2. The viral load is elevated.
The American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases
Society of America (IDSA) have issued guidelines for the treatment of Hepatitis C. It is their
position that evidence clearly supports treatment in all HCV-infected persons except those with
a limited life expectancy due to non-liver related co-morbid conditions. For those patients who
previously failed a protease inhibitor, there are two recommendations for genotype 1 without
cirrhosis. One option is Daclatasvir and sofosbuvir. Another recommended regimen is Harvoni
with or without ribavirin.
This patient has chronic Hepatitis C. The AASLD and IDSA guidelines do not require that a
patient have cirrhosis in order to be treated. In the ION-2 trial 440 treatments experienced
patients received Harvoni with a 94-96% Sustained Virologic Response (SVR) rate. There is no
reason to wait for the patient to develop either cirrhosis or hepatocellular carcinoma. Harvoni is
recommended by the AASLD and IDSA for genotype 1 and is appropriate therapy.
Reference:
1- American Association for the Study of Liver Diseases and Infectious Diseases Society of
America, HCV Guidance, Recommendations for Testing, Managing and Treating Hepatitis
c, 2015.
Should you have any questions in regard to this review determination, please do not hesitate to contact
me or Terese Giorgio at (516) 209-5411, fax number 516 326-1034.
Sincerely,
L~.4~M7'.
Frank E. laquinta, MD
Medical Consultant
FEI: jt